Altogether, our findings establish an important role for MALT1-mediated CYLD cleavage in BCR signaling, canonical NF-κB activity, and consequently cell growth of BCR-dependent lymphomas, thereby providing novel insights into targeting MALT1 protease activity and ubiquitination enzymes as a promising therapeutic approach for these aggressive lymphomas. This evidence concerns the gene BCR and lymphoma.